Live attenuated measles virus vaccine therapy for locally established malignant glioblastoma tumor cells

Abstract: Glioblastoma multiforme is the most aggressive malignant primary brain tumor in humans, with poor prognosis. A new glioblastoma cell line (ANGM5) was established from a cerebral glioblastoma multiforme in a 72-year-old Iraqi man who underwent surgery for an intracranial tumor. This study was carried out to evaluate the antitumor effect of live attenuated measles virus (MV) Schwarz vaccine strain on glioblastoma multiforme tumor cell lines in vitro. Live attenuated MV Schwarz strain was propagated on Vero, human rhabdomyosarcoma, and human glioblastoma-multiform (ANGM5) cell lines. The infected confluent monolayer appeared to be covered with syncytia with granulation and vacuolation, as well as cell rounding, shrinkage, and large empty space with cell debris as a result of cell lysis and death. Cell lines infected with virus have the ability for hemadsorption to human red blood cells after 72 hours of infection, whereas no hemadsorption of uninfected cells is seen. Detection of MV hemagglutinin protein by monoclonal antibodies in infected cells of all cell lines by immunocytochemistry assay gave positive results (brown color) in the cytoplasm of infected cells. Cell viability was measured after 72 hours of infection by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Results showed a significant cytotoxic effect for MV (P<0.05) on growth of ANGM5 and rhabdomyosarcoma cell lines after 72 hours of infection. Induction of apoptosis by MV was assessed by measuring mitochondrial membrane potentials in tumor cells after 48, 72, and 120 hours of infection. Apoptotic cells were counted, and the mean percentage of dead cells was significantly higher after 48, 72, and 120 hours of infection compared with control cells. This study concludes that live attenuated MV Schwarz vaccine induces the oncolytic effect in Iraqi tumor cell line ANGM5 and in the rhabdomyosarcoma cell line through syncytia in tumor cells, which is one of the causes of cell death. The MV vaccine strain has the ability to insert its hemagglutinin protein into the tumor cell surface, leading to modification of the antigenic surface of tumor cells that may induce an antitumor immune response, MV vaccine strain induced cell killing by direct cytolysis and apoptosis induction. These antitumor features may indicate the use of MV in the treatment of glioblastoma.

Keywords: virotherapy, glioblastoma multiforme

Introduction

Glioblastomas (GBMs) are the most frequent primary tumors of the central nervous system in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors.1 During the last 2 decades, the paradigm for cancer treatment has developed from relatively non-specific cytotoxic agents to selective, mechanism-based therapeutics.2 Targeted approaches aim to inhibit molecular pathways that are crucial for tumor growth
and maintenance.\textsuperscript{3} Oncolytic viruses are defined by their ability to specifically target tumor cells while leaving the normal tissues safe. Their most characteristic features are their target selectivity and their cytolytic capacity, as well as the ability to recruit uninfected neighboring cells (syncytia formation), the ability to infect dividing and nondividing cells, a high stability in vivo, the inability to perform chromosomal integration, and the lack of disease induction.\textsuperscript{4} Numerous viruses are now being considered as potential cancer therapeutics, including the vaccine strain of measles virus (MV). MV is an envelope and negative, nonsegmented, single-strand RNA virus belonging to the \textit{Morbillivirus} genus of the Paramyxoviridae family.\textsuperscript{5} The attenuated strain of measles readily lyses transformed cells, whereas replication and lysis are limited in normal human cells. It has a number of features that make it highly suitable for further development as an oncolytic agent, among them stability and a long history of safety in human use. These features are being combined with its ready potential for genetic manipulations to generate recombinant MVs with desirable therapeutic attributes.\textsuperscript{6} Peng et al reported that a growing interest in onco-virotherapy, using a number of replication-competent (oncolytic) viruses such as MV for cancer therapy, has emerged.\textsuperscript{7} Previous studies have proved that different MV strains demonstrated potent oncolytic efficacy with minor or no adverse effects against multiple primary and established cancer cell lines and several preclinical animal tumor models, including both solid tumors and hematologic malignancies such as ovarian cancer. Zhang et al showed that a large variety of oncolytic viruses have been engineered, and among the many oncolytic virus systems, the attenuated Edmonston vaccine strain of the MV has proven safe and effective.\textsuperscript{8} Al-Shamery et al concluded that the Iraqi strain of Newcastle disease virus had the ability to replicate in different cell types of tumors and to insert their H protein in the tumor cell surface that leads to modifying the antigenic determinants and increasing the immunogenicity of the tumor cell surface. Thus, the modification of tumor induces the attachment of CD4 and CD8 T cells on an infected tumor cell surface.\textsuperscript{9} Another study of Al-Shamery et al\textsuperscript{10} revealed that Iraqi strain of Newcastle disease virus, when used as an oncolytic agent by intratumoral injection, showed a significant stimulation in immune response by increasing the level of interleukin 2 and interferon \(\gamma\) and increasing the percentage of CD8 and CD56 cell in tumor sections.\textsuperscript{10} This study aims to investigate the oncolytic ability of measles vaccine strain on a GBM tumor cell line derived from an Iraqi patient.

**Methods**

**Live attenuated virus vaccine against measles (Schwarz strain)**

Schwarz strain (Aventis Pasteur SA, Lyon, France) was obtained by personal communication.

**Cell culture**

The GBM multiform (ANGM5) cell line was supplied by the Iraqi Center for Cancer and Medical Genetic Researches (ICCMGR). The patient from whom the tumor was derived was a 72-year-old man who was admitted to the neurosurgery hospital in 2005 in Baghdad, Iraq. The patient presented with left-sided hemipareses of 1 month's duration, with headache and blurred vision. The patient did not receive chemotherapy or radiation therapy before the operation. A magnetic resonance imaging scan showed a right parieto-occipital mass, which was then resected. A tumor specimen (1.5 cm\(^3\)) was excised and used to establish the cell line. The pathological diagnosis was GBM multiforme, based on the histological features of vascular proliferation, hypercellularity, high mitotic index, gemistocytic nuclei, and necrosis. Al-Shamery et al proved the GBM cell line (ANMG5) was resistant to chemotherapy.\textsuperscript{9,11}

Vero (African green monkey) cell line and human rhabdomyosarcoma (RD) cell lines were supplied by ICCMGR, cell bank unit; these cells, including ANGM5, were grown at 37°C in Roswell Park Memorial Institute medium, as recommended by ICCMGR. All media contained 200 U/mL penicillin and 100 U/mL streptomycin and were supplemented with 10% fetal bovine serum (Cellgro, Manassas, VA USA), according to cell types.

**MV propagation**

MV was propagated by infecting 1.5\(\times\)10\(^8\) Vero cells in T25 flasks in 3 mL serum-free Minimum Essential Medium (MEM; US Biological, Salem, MA, USA) at 37°C for 2 hours, and then the medium was replaced with serum-free media. The cells were incubated at 37°C for 3–5 days and subsequently harvested in 1 mL MEM (US Biological). The viruses were then released by three cycles of freezing and thawing. The titers of viral stocks were determined by 50% end-point dilution assays on Vero cells in 96-well plates.

**Studying the cytopathic effect of MV and hemadsorption test**

**Cell seeding**

Cancer cells (RD and ANGM5) and Vero cells were dispersed with trypsin-ethylenediaminetetraacetic acid (US Biological) and suspended in growth media with 10% fetal calf serum, and 1–3 mL cell suspension (1\(\times\)10\(^5\) cells/dish) was seeded
in plastic tissue culture Petri dishes that contain sterile cover slips. Cells were incubated at 37°C for 24 hours or until a confluent monolayer formed.12

Cell infection
The procedure of infection with MV was carried out by removing the old media that contain serum and adding 1 mL of the virus solution (concentrated inoculums =3.4×10⁵) for 2 hours at room temperature, with shaking, to allow virus attachment and penetration. After that, cells were washed with phosphate-buffered saline (PBS), and serum-free medium was added. Cells were incubated for 3 days or until cytopathic effect appeared.13

Preparation of 1% human red blood cell solution
Blood was collected from healthy persons in a heparinized tube and washed three times with PBS by centrifugation at 1,000 rpm at 4°C, the supernatant was discarded, 0.1 mL cell pellet was transferred to a sterile graduated tube, and the volume was completed to 10 mL with PBS. Hemadsorption of cell culture infected with MV was carried out according to Haas et al.15 RD, GBM, and Vero cell line infected with MV were washed three times with PBS after removing the old media. An aliquot of 1 mL 1% human red blood cell (RBC) solution was added to cell sections. Cells were incubated with the RBC solution for 30 minutes at 4°C and then washed two times with PBS to remove nonadsorbed RBCs. Finally, adsorbed RBCs were fixed by adding 1 mL 4% formaldehyde and cells incubated for 30 minutes at 4°C. This experiment was done in the presence of control groups of cancer cells not infected with MV.

Hematoxylin and eosin staining
Cell sections were immersed in hematoxylin solution for 5 minutes and washed in distilled water for three changes. Then cell sections were immersed in eosin solution for 2–3 minutes. Cell sections were dehydrated by being immersed in 95% alcohol for 1 minute, and then two changes were made in absolute alcohol for 2 minutes each. Clearing was made by adding xylene for 1 minute, and then absolute alcohol was added for 2 minutes to remove xylene. Finally, cell sections were mounted with xylene-based mounting medium.

Detection of MV hemagglutinin protein
This was done by using immunoperoxidase kit for staining of cell lines infected with MV. Measles hemagglutinin (H; 6016) is a monoclonal antibody against the Edmonston strain of MV. The principle of the test is that the primary antibody (monoclonal antibody) binds to the H protein of MV, and the secondary antibody binds to determinants on the primary antibody. Then the avidin containing the horseradish peroxidase enzyme was allowed to bind to the biotin molecule attached to the secondary antibody. The staining procedure was done as recommended by the manufacturer (Santa Cruz Biotechnology, Dallas, TX, USA).

Studying the oncolytic effect of MV on RD and GMB
For cell viability assays, 7×10⁵ cells/50 µL were plated into 96-well plates and infected with the live-attenuated MV vaccine at twofold dilution. At the end of the incubation period, the virus was removed, and the cells were maintained in serum-free media. At 1, 2, 3, 4, and 5 days after infection, cell viability was determined by the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. That measures the formation of insoluble formazan by mitochondria in viable cells. The reaction was subsequently discontinued by lysing the cells with 200 µL dimethyl sulfoxide for 15 minutes. Quantification measurements (optical density) were obtained at a wavelength of 550 nm, using spectrophotometric analysis.12

Apoptosis induction in vitro
GBM cells (ANGM5), RD, and control cells were cultured in plastic tissue culture Petri dishes. After 70% confluency (18–24 hours), cells were infected with MV for 48, 72, and 120 hours. Each virus incubation period was done with three replicas.

Before use, MitoCapture™ (US Biological) was diluted at a ratio 1:1,000 by mixing 1 µL MitoCapture™ to 1 mL prewarmed incubation buffer and mixing well by vortex. MitoCapture™ is poorly soluble in aqueous solutions. To remove nonsoluble particles, the dye solution was centrifuged for 1 minute at 13,000 rpm and carefully transferred to the supernatant without disturbing pellet debris, and then 0.4 mL diluted MitoCapture™ solution was added to adherent cells and incubated at 37°C for 15–20 minutes in the dark.

Cells were washed with prewarmed incubation buffer three times, and then 0.4 mL of the prewarmed incubation buffer was added.

Cells were examined immediately under a fluorescent microscope, using a band-pass filter (detects fluorescein and rhodamine). MitoCapture™ that has aggregated in the mitochondria of healthy cells gives off red light. In apoptotic
cells, MitoCapture™ cannot accumulate in the mitochondria but remains as monomers in the cytoplasm and gives off green light.

The results were calculated by counting apoptotic cells and using Image J program version 1.47 (National Institutes of Health, Bethesda, MD, USA). This program is an image processing and analysis program that can create density histograms. It converted the images from MitoCapture™ to histograms by showing the number of pixels of each value, regardless of location, and the mean and maximum values. The log display allows for the visualization of minor components.\(^\text{16}\)

**Statistical analysis**

A paired sample *t*-test was used within the SPSS program (version 20) for analysis of data. The difference was considered significant when *P*≤0.05.

**Results and discussion**

**Cytotoxic effect of MV on RD and GBM cell lines in vitro**

The typical cytopathic effect of MV was the formation of mononuclear cell aggregates (syncytia) caused by cell–cell fusion.\(^\text{17}\) The MV shows a high ability for

---

**Figure 1** Propagation of measles virus on Vero, rhabdomyosarcoma (RD), and ANGMS cell lines.

**Notes:**
- (A) Vero cell line uninfected with measles virus, 100×.
- (B) Vero cells infected with measles virus, showing syncytial formation and cell granulation after 72 hours of infection, 40×.
- (C) Vero cells infected with measles virus, showing syncytial formation and cell granulation after 120 hours of infection, 40×.
- (D) RD cell line uninfected with measles virus, 100×.
- (E) RD cell line infected with measles virus, showing syncytial formation and cell granulation after 72 hours of infection (arrows), 40×.
- (F) RD cell line infected with measles virus, showing syncytial formation and cell granulation after 120 hours of infection, 40×.
- (G) ANGMS cell line uninfected with measles virus, 20×.
- (H) ANGMS cell line infected with measles virus, showing syncytial formation and cell granulation after 72 hours of infection, 40×.
- (I) ANGMS cell line infected with measles virus, showing syncytial formation and cell granulation after 120 hours of infection, 40×.
propagation and lysis of Vero cells. After 120 hours of exposure, alterations in the morphological characteristics of Vero cells were cell rounded shrinkage, clustered cells, and large empty space with cell debris as a result of cell lysis and death. Although no morphological alteration was observed in uninfected cells, MV shows the same effect on RD and GBM cells (Figures 1 and 2).

**Hemadsorption effect of MV**

Results showed that all cell lines (Vero, RD, and GBM) infected with virus have the ability for hemadsorption of human RBCs after 72 hours of infection, whereas uninfected cells gave negative results for hemadsorption (Figure 3).

**Detection of MV H protein in infected cell lines**

Monoclonal antibodies specific for H protein of MV in Vero, RD, and GBM cell lines after 72 and 120 hours of virus infection showed that H protein was found in the cytoplasm of infected cells, appearing as a stained brown color; uninfected cell cytoplasm was negative-stained. The nuclei of infected and uninfected cells both gave off a blue color (Figures 4–6).

**Cytotoxic effect of MV on RD and GBM**

Results in Figure 7 showed a significant cytotoxic effect for MV ($P \leq 0.05$) on the growth of the RD cell line at the first and second dilution, with a growth inhibition percentage of 56.778% and 60.439%, respectively, after 72 hours of infection. When the dilution increased, there was a significant decline in the inhibitory effect, with a significant cytotoxic effect when compared to the control (displaying growth inhibition percentages of 38.616%, 31.039%, and 19.801%, respectively).
addition, concentrated inoculums of MV showed a significant cytotoxic effect when compared with the control; growth inhibition percentage was 41.298%, as shown in Figure 7.

Results in Figure 8 showed the cytotoxic effect of MV on RD cells after 120 hours of infection. A significant cytotoxic effect (P<0.05) on the growth of the RD cell line was seen at dilutions 1, 2, and 3 when compared with the control, with a growth inhibition percentage of 53.110%, 69.954%, and 53.717%, respectively. A concentrated inoculum of MV showed a significant cytotoxic effect when compared with the control, with a growth inhibition percentage of 13.050%.

The cytotoxic inhibition rate was significantly decreased when the dilution increased. There were significant effects at dilutions 4, 5, and 6, with a growth inhibition percentage of 31.714%, 15.174%, and 5.918%, respectively.

The MV had a significant effect on GBM cells after 72 hours of exposure when compared with the control at dilutions 1, 2, and 3, with a growth inhibition percentage of 46.047%, 73.183%, and 58.012%, respectively. A significant decrease in cytotoxic inhibition rate was recorded when the dilution increased, with a significant cytotoxic effect at dilutions 4, 5, and 6, with percentage of growth inhibition at 27.350%, 19.658%, and 14.529%, respectively. A concentrated inoculum of MV showed a significant cytotoxic effect when compared with the control, with a growth inhibition percentage of 46.047%, as shown in Figure 9.
Measles virus vaccine as an antiglioblastoma agent

Figure 7 Cytotoxic effect of concentrated and diluted inoculum of measles virus on rhabdomyosarcoma cell line after 72 hours of infection.
Abbreviation: GI%, growth inhibition percentage.

Figure 8 Cytotoxic effect of concentrated and diluted inoculum of measles virus on the rhabdomyosarcoma cell line after 120 hours of infection.
Abbreviation: GI%, growth inhibition percentage.

Figure 9 Cytotoxic effect of concentrated and diluted inoculum of measles virus on the glioblastoma cell line after 72 hours of infection.
Abbreviation: GI%, growth inhibition percentage.
Figure 10 Cytotoxic effect of concentrated and diluted inoculum of measles virus on the glioblastoma cell line after 120 hours of infection. Abbreviation: GI%, growth inhibition percentage.

Figure 11 Rhabdomyosarcoma cell line infected with measles virus at different incubation periods. Abbreviation: MV, measles virus.

Figure 12 Glioblastoma cell line infected with measles virus at different incubation periods. Abbreviation: MV, measles virus.
Figure 10 showed that the cytotoxic effect of MV on GBM cells after 120 hours of exposure was significantly higher ($P<0.05$) on the growth of the GBM cell line at dilutions 1, 2, and 3 compared with the control, with growth inhibition percentages of 87.817%, 90.101%, and 74.746%, respectively. A concentrated inoculum of MV showed a significant cytotoxic effect when compared with the control, with a growth inhibition percentage of 35.279%. The cytotoxic inhibition rate was significantly decreased when the dilution increased, with a significant effect at dilutions 4, 5, and 6, with a growth inhibition percentage of 48.477%, 36.421%, and 23.477%, respectively.

**Mitochondrial permeability transition apoptosis test**

Results, as shown in Figure 11, indicate that MV induces apoptosis in RD cell lines stained with MitoCapture™ (US Biological), and the means percentages of apoptotic cells were significantly higher (87.42%, 93.69%, and 97.36%, respectively) after 48, 72, and 120 hours of infection in comparison with uninfected RD cells (20.83%). Moreover, the means percentage of apoptotic cells was significantly lower in uninfected GBM cells (22.99%). Significant differences were recorded in GBM cells infected with MV after 48, 72, and 120 hours of infection (89.62%, 95.43%, and 97.97%, respectively) (Figure 12). In addition, the amounts of green and red fluorescence in the cells were statistically analyzed and showed as histograms using ImageJ program (National Institutes of Health) (Figures 13, 14 and 15).

**Discussion**

Results showed that the live attenuated MV vaccine successfully passaged and replicated on the Iraqi GBM tumor cell line ANGM5, African green monkey kidney cells (Vero cell line), and RD cells. Vero cells are susceptible to infection by MV. It is known that viruses enter through natural measles receptor CD46 and spread by cell–cell fusion, causing giant syncytia formation and killing the tumor cells. The results of this study showed that MV Schwarz strain efficiently kills tumor cells and causes an obvious cytopathic effect on infected cell lines 72–120 hours after infection. The cytopathic effect of MV begins after the viral H protein interacts with its receptor (CD46) on a target cell. This interaction triggers conformational changes in the viral fusion protein, which lead to fusion of the viral and cell plasma membranes, allowing the viral nucleoprotein...
complex to enter into the cell. The H protein interacts with CD46 on neighboring cells and can trigger membrane fusion between cells. As the expression of the viral H and fusion proteins increases, the probability that an infected cell will fuse with a neighboring tumor cell increases. Once two cells fuse, there is an effective decrease in the concentration of viral proteins expressed on the cell surfaces, and therefore, there is a delay in the spread of fusion until additional proteins are expressed on the surface. In time, this spread of cell-to-cell fusion leads to the formation of giant cell syncytia, which normally die after a few days.20,21

Infected cells that have been incorporated into syncytia stop replicating and do not contribute to further growth of the tumor population. In addition, once infected cells die, they might release free virus particles that can infect surrounding cells.22

Results of a hemadsorption test showed that the cells infected with virus for 72 hours have a positive result because MV contains a surface glycoprotein known as hemagglutinin. These cells are capable of binding RBCs. When viruses replicate on cell culture, H molecules appear on the cell surface. If human RBCs are added to the cell culture in which the virus is replicating, they will adhere to the cell sheet in a phenomenon known as hemadsorption. The presence of hemadsorbing viruses can therefore be detected several days before a cytopathic effect becomes apparent;23 uninfected cells have negative results on the hemadsorption test.

In this study, the result of a cytotoxicity test of live attenuated MV on human cancer cells (RD and GBM) after 72 and 120 hours showed that concentrated inoculums and higher dilutions of MV have a low cytotoxic inhibition rate, and the low dilutions of MV caused a higher cytotoxic inhibition rate. This result highlights the competition among viral replication, tumor cell growth, and the death rate of infected tumor cells.24 Dingli et al25 reported that the virus,
Measles virus vaccine as an antiglioblastoma agent

in high concentration, cannot infect tumor cells because the surface receptors of tumor cells will be saturated with virus ligands. Moreover, Wodarz reported that very low concentrations of virus that have infected cells are not available to infect additional cells, leading to a potential imbalance in the virotherapy.

Results of the cytotoxic effect and apoptosis of MV showed that the live attenuated MV vaccine has a natural ability to specifically kill a variety of human tumor cells. It exerts its cytopathic effect by fusing infected cells with the surrounding cells, forming multinucleated syncytia, which is followed by cell death by apoptotic or nonapoptotic mechanisms to a variety

---

**Figure 15** Histogram of images analysis of mitochondrial permeability transition apoptosis test of Glioblastoma (GBM) cell line, 40x.

**Notes:** (A) GBM cells uninfected with measles virus. The mean of red color for nonapoptotic cells was 44.979. The mean of green color for apoptotic cells was 12.90, so the percentage of apoptotic cells was 28.68%. (B) GBM cells infected with measles virus after 48 hours. The mean of red color for nonapoptotic cells was 5.46. The mean of green color for apoptotic cells was 52.66, so the percentage of viable cells was 10.36%. (C) GBM cells infected with measles virus after 72 hours. The mean of red color for nonapoptotic cells was 1.04. The mean of green color for apoptotic cells was 23.09, so the percentage of viable cells was 4.50%. (D) GBM cells infected with measles virus after 120 hours. The mean of red color for nonapoptotic cells was 0.62. The mean of green color for apoptotic cells was 21.42, so the percentage of viable cells was 2.89%.

**Abbreviations:** StdDev, standard deviation; Min, minimum; Max, maximum.
of human tumor cells. This selectivity results from the entry of MV: attenuated MV enters the cell via receptor CD46, which is overexpressed on tumor cells. MV is a lytic virus, and MV replication in tumor cells leads to lysis of cancer cells. In addition, MV induces apoptosis. Zhou et al. reported that the live-attenuated MV vaccine could potentially induce apoptosis in ovarian cancer cells because the live-attenuated MV vaccine possesses antitumor activity against ovarian cancer in vitro through aberrant reactive oxygen species activation-mediated epigenetic silencing of E-cadherin and lays the theoretical foundation for the clinical application of the live-attenuated MV vaccine in the treatment of ovarian cancer.

Conclusion

MV vaccine strains replicate efficiently in GBM tumor cells as well as in Vero and RD cells and can be further investigated for future use as GBM recommended therapy.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Amartya D, Bala NN, Bhattacharjee A. Treatment of glioblastoma multiforme. JPMBS. 2011;1(26).